Hindalco, Bharti Airtel, Cipla, UPL and Eicher Motors were among the top losers on NSE.

Aarvi Encon, KEI Industries, Gokaldas Export, SEL Manufact and SecUR Credentials, hit their fresh 52-week highs at 10:09AM.

Cipla reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021...

Total revenue from operations was at Rs 5,478.86 crore against ET NOW poll of Rs 5,420 crore.

In a release last month, the Ministry of Chemicals and Fertilisers said that 55 companies had qualified for the PLI scheme for the pharmace...

Revenues for the quarter rose 10.3 per cent YoY to Rs 5,485.84 crore compared with Rs 4,972.58 crore in the same quarter last year.

The BSE Healthcare index was trading 0.49 per cent up at 13,978 around 12:30 pm.

Consumer stocks stole the show with Nifty FMCG surging 2.36 per cent to close at 26,459.55.

Barring telecom, energy and oil & gas, all other sectoral indices were trading in the green on BSE.

Hold Cipla Ltd. at a price target of Rs 585. The Cipla management has guided for a double-digit growth in the US and India businesses.

The construction of the new facility is scheduled to start early next year, with full operations expected to commence in the third quarter ...

Drug firm Cipla will invest around Rand 1.3 billion (over Rs 590 crore) to launch a manufacturing facility in South Africa for the producti...

Drug major Cipla today announced completion of selling its entire holding in Hong Kong-based Biomab Holding to Biomab Brilliant for $ 2.5 m...

Drug major Cipla has entered into an agreement to sell its entire stake in Biomab Holding to Biomab Brilliant for a consideration of $25,77...

The government is set to put Zanamivir, the only swine flu drug that is freely available in the market, currently, under restricted sale ca...

Ranbaxy Laboratories, India’s largest pharma company by sales, is looking to shift its marketing and administrative teams from its Gurgaon ...

Pakistan has now become a new market for Indian oncology drug manufacturers and their entry may lower the prices of anti-cancer drugs in th...